BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu S, Guo W, Shi J, Li N, Yu X, Xue J, Fu X, Chu K, Lu C, Zhao J. MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol. 2012;56:389-396. [PMID: 21888875 DOI: 10.1016/j.jhep.2011.08.008] [Cited by in Crossref: 109] [Cited by in F6Publishing: 109] [Article Influence: 9.9] [Reference Citation Analysis]
Number Citing Articles
1 Ali ME, Halby HM, Ali MY, Hassan EA, El-Mokhtar MA, Sayed IM, Thabet MM, Fouad M, El-Ashmawy AM, Mahran ZG. Role of Serum Vitamin D, Interleukin 13, and microRNA-135a in Hepatocellular Carcinoma and Treatment Failure in Egyptian HCV-Infected Patients Receiving Direct Antiviral Agents. Viruses 2021;13:2008. [PMID: 34696438 DOI: 10.3390/v13102008] [Reference Citation Analysis]
2 Wang W, Lin H, Zhou L, Zhu Q, Gao S, Xie H, Liu Z, Xu Z, Wei J, Huang X, Zheng S. MicroRNA-30a-3p inhibits tumor proliferation, invasiveness and metastasis and is downregulated in hepatocellular carcinoma. Eur J Surg Oncol 2014;40:1586-94. [PMID: 24290372 DOI: 10.1016/j.ejso.2013.11.008] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 5.2] [Reference Citation Analysis]
3 Gupta M, Akhtar J, Sarwat M. MicroRNAs: Regulators of immunological reactions in hepatocellular carcinoma. Semin Cell Dev Biol 2021:S1084-9521(21)00134-8. [PMID: 34049801 DOI: 10.1016/j.semcdb.2021.05.025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Liu X, Li M, Hou M, Huang W, Song J. MicroRNA-135a alleviates oxygen-glucose deprivation and reoxygenation-induced injury in neurons through regulation of GSK-3β/Nrf2 signaling. J Biochem Mol Toxicol 2018;32:e22159. [DOI: 10.1002/jbt.22159] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
5 Zhuang L, Xu L, Wang P, Meng Z. Serum miR-128-2 serves as a prognostic marker for patients with hepatocellular carcinoma. PLoS One. 2015;10:e0117274. [PMID: 25642945 DOI: 10.1371/journal.pone.0117274] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
6 Joshi T, Elias D, Stenvang J, Alves CL, Teng F, Lyng MB, Lykkesfeldt AE, Brünner N, Wang J, Gupta R, Workman CT, Ditzel HJ. Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer. Oncotarget 2016;7:57239-53. [PMID: 27528030 DOI: 10.18632/oncotarget.11136] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
7 Branco-Price C, Zhang N, Schnelle M, Evans C, Katschinski DM, Liao D, Ellies L, Johnson RS. Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic success. Cancer Cell 2012;21:52-65. [PMID: 22264788 DOI: 10.1016/j.ccr.2011.11.017] [Cited by in Crossref: 99] [Cited by in F6Publishing: 96] [Article Influence: 9.9] [Reference Citation Analysis]
8 Yeh TS, Wang F, Chen TC, Yeh CN, Yu MC, Jan YY, Chen MF. Expression profile of microRNA-200 family in hepatocellular carcinoma with bile duct tumor thrombus. Ann Surg 2014;259:346-54. [PMID: 24135722 DOI: 10.1097/SLA.0000000000000223] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
9 Kalathil D, John S, Nair AS. FOXM1 and Cancer: Faulty Cellular Signaling Derails Homeostasis. Front Oncol 2020;10:626836. [PMID: 33680951 DOI: 10.3389/fonc.2020.626836] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
10 Schemionek M, Kharabi Masouleh B, Klaile Y, Krug U, Hebestreit K, Schubert C, Dugas M, Büchner T, Wörmann B, Hiddemann W, Berdel WE, Brümmendorf TH, Müller-Tidow C, Koschmieder S. Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia. PLoS One 2015;10:e0125783. [PMID: 25996952 DOI: 10.1371/journal.pone.0125783] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
11 Zeng YB, Liang XH, Zhang GX, Jiang N, Zhang T, Huang JY, Zhang L, Zeng XC. miRNA-135a promotes hepatocellular carcinoma cell migration and invasion by targeting forkhead box O1. Cancer Cell Int 2016;16:63. [PMID: 27486383 DOI: 10.1186/s12935-016-0328-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 6.8] [Reference Citation Analysis]
12 Wu M, Zhao H, Guo L, Wang Y, Song J, Zhao X, Li C, Hao L, Wang D, Tang J. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer. Drug Deliv 2018;25:226-40. [PMID: 29313393 DOI: 10.1080/10717544.2017.1422300] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 11.3] [Reference Citation Analysis]
13 Catanzaro G, Besharat ZM, Garg N, Ronci M, Pieroni L, Miele E, Mastronuzzi A, Carai A, Alfano V, Po A, Screpanti I, Locatelli F, Urbani A, Ferretti E. MicroRNAs-Proteomic Networks Characterizing Human Medulloblastoma-SLCs. Stem Cells Int 2016;2016:2683042. [PMID: 26880947 DOI: 10.1155/2016/2683042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhu J, Yin T, Xu Y, Lu XJ. Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions. J Cell Physiol. 2019;234:12122-12132. [PMID: 30644100 DOI: 10.1002/jcp.28048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
15 Hu Y, Yu X, Xu G, Liu S. Metastasis: an early event in cancer progression. J Cancer Res Clin Oncol 2017;143:745-57. [DOI: 10.1007/s00432-016-2279-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
16 Jiang Y, Tao Y, Zhang X, Wei X, Li M, He X, Zhou B, Guo W, Yin H, Cheng S. Loss of STAT5A promotes glucose metabolism and tumor growth through miRNA-23a-AKT signaling in hepatocellular carcinoma. Mol Oncol 2021;15:710-24. [PMID: 33155364 DOI: 10.1002/1878-0261.12846] [Reference Citation Analysis]
17 Han TS, Hur K, Cho HS, Ban HS. Epigenetic Associations between lncRNA/circRNA and miRNA in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2622. [PMID: 32937886 DOI: 10.3390/cancers12092622] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
18 Díaz-Beyá M, Brunet S, Nomdedéu J, Tejero R, Díaz T, Pratcorona M, Tormo M, Ribera JM, Escoda L, Duarte R, Gallardo D, Heras I, Queipo de Llano MP, Bargay J, Monzo M, Sierra J, Navarro A, Esteve J; Cooperative AML group CETLAM (Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias). MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia 2014;28:804-12. [PMID: 24072101 DOI: 10.1038/leu.2013.281] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
19 Khare S, Zhang Q, Ibdah JA. Epigenetics of hepatocellular carcinoma: Role of microRNA. World J Gastroenterol 2013; 19(33): 5439-5445 [PMID: 24023486 DOI: 10.3748/wjg.v19.i33.5439] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 43] [Article Influence: 5.9] [Reference Citation Analysis]
20 Wu L, Bai X, Xie Y, Yang Z, Yang X, Lin J, Zhu C, Wang A, Zhang H, Miao R, Wu Y, Robson SC, Zhao Y, Sang X, Zhao H. MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development: microRNA; hepatocellular carcinoma; metastasis. Hepatol Res 2017;47:80-94. [DOI: 10.1111/hepr.12737] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Wang JC, Xia AL, Xu Y, Lu XJ. Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis. J Cell Physiol. 2019;234:1062-1070. [PMID: 30256409 DOI: 10.1002/jcp.27324] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
22 Sodroski C, Lowey B, Hertz L, Jake Liang T, Li Q. MicroRNA-135a Modulates Hepatitis C Virus Genome Replication through Downregulation of Host Antiviral Factors. Virol Sin. 2019;34:197-210. [PMID: 30456659 DOI: 10.1007/s12250-018-0055-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
23 Mao XW, Xiao JQ, Li ZY, Zheng YC, Zhang N. Effects of microRNA-135a on the epithelial-mesenchymal transition, migration and invasion of bladder cancer cells by targeting GSK3β through the Wnt/β-catenin signaling pathway. Exp Mol Med 2018;50:e429. [PMID: 29350680 DOI: 10.1038/emm.2017.239] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
24 Song SK, Jung WY, Park SK, Chung CW, Park Y. Significantly different expression levels of microRNAs associated with vascular invasion in hepatocellular carcinoma and their prognostic significance after surgical resection. PLoS One. 2019;14:e0216847. [PMID: 31513595 DOI: 10.1371/journal.pone.0216847] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
25 Wierstra I. The transcription factor FOXM1 (Forkhead box M1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles. Adv Cancer Res 2013;118:97-398. [PMID: 23768511 DOI: 10.1016/B978-0-12-407173-5.00004-2] [Cited by in Crossref: 93] [Cited by in F6Publishing: 68] [Article Influence: 10.3] [Reference Citation Analysis]
26 Tang Y, Liu S, Li N, Guo W, Shi J, Yu H, Zhang L, Wang K, Liu S, Cheng S. 14-3-3ζ promotes hepatocellular carcinoma venous metastasis by modulating hypoxia-inducible factor-1α. Oncotarget 2016;7:15854-67. [PMID: 26910835 DOI: 10.18632/oncotarget.7493] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
27 Tang W, Jiang Y, Mu X, Xu L, Cheng W, Wang X. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression. Cell Signal 2014;26:1420-6. [PMID: 24607788 DOI: 10.1016/j.cellsig.2014.03.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
28 Yuan F, Yun Y, Fan H, Li Y, Lu L, Liu J, Feng W, Chen SY. MicroRNA-135a Protects Against Ethanol-Induced Apoptosis in Neural Crest Cells and Craniofacial Defects in Zebrafish by Modulating the Siah1/p38/p53 Pathway. Front Cell Dev Biol 2020;8:583959. [PMID: 33134300 DOI: 10.3389/fcell.2020.583959] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Tan W, Li Y, Lim SG, Tan TM. miR-106b-25/miR-17-92 clusters: Polycistrons with oncogenic roles in hepatocellular carcinoma. World J Gastroenterol 2014; 20(20): 5962-5972 [PMID: 24876719 DOI: 10.3748/wjg.v20.i20.5962] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 65] [Article Influence: 7.8] [Reference Citation Analysis]
30 Zhuang LP, Meng ZQ. Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival. Biomed Res Int. 2015;2015:731781. [PMID: 25688365 DOI: 10.1155/2015/731781] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
31 Han LL, Lv Y, Guo H, Ruan ZP, Nan KJ. Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy. World J Gastroenterol 2014; 20(30): 10249-10261 [PMID: 25132742 DOI: 10.3748/wjg.v20.i30.10249] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
32 Cao Z, Qiu J, Yang G, Liu Y, Luo W, You L, Zheng L, Zhang T. MiR-135a biogenesis and regulation in malignancy: a new hope for cancer research and therapy. Cancer Biol Med 2020;17:569-82. [PMID: 32944391 DOI: 10.20892/j.issn.2095-3941.2020.0033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
33 Cheng Z, Liu F, Zhang H, Li X, Li Y, Li J, Liu F, Cao Y, Cao L, Li F. miR-135a inhibits tumor metastasis and angiogenesis by targeting FAK pathway. Oncotarget 2017;8:31153-68. [PMID: 28415713 DOI: 10.18632/oncotarget.16098] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
34 Wang R, Zhao N, Li S, Fang JH, Chen MX, Yang J, Jia WH, Yuan Y, Zhuang SM. MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology. 2013;58:642-653. [PMID: 23468064 DOI: 10.1002/hep.26373] [Cited by in Crossref: 144] [Cited by in F6Publishing: 140] [Article Influence: 18.0] [Reference Citation Analysis]
35 Skrzypek K, Tertil M, Golda S, Ciesla M, Weglarczyk K, Collet G, Guichard A, Kozakowska M, Boczkowski J, Was H, Gil T, Kuzdzal J, Muchova L, Vitek L, Loboda A, Jozkowicz A, Kieda C, Dulak J. Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis. Antioxid Redox Signal 2013;19:644-60. [PMID: 23617628 DOI: 10.1089/ars.2013.5184] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 10.6] [Reference Citation Analysis]
36 Heo MJ, Yun J, Kim SG. Role of non-coding RNAs in liver disease progression to hepatocellular carcinoma. Arch Pharm Res 2019;42:48-62. [PMID: 30610616 DOI: 10.1007/s12272-018-01104-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
37 Guo R, Hao G, Bao Y, Xiao J, Zhan X, Shi X, Luo L, Zhou J, Chen Q, Wei X. MiR-200a negatively regulates TGF-β 1 -induced epithelial-mesenchymal transition of peritoneal mesothelial cells by targeting ZEB1/2 expression. American Journal of Physiology-Renal Physiology 2018;314:F1087-95. [DOI: 10.1152/ajprenal.00566.2016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
38 Li C, Zhang K, Chen J, Chen L, Wang R, Chu X. MicroRNAs as regulators and mediators of forkhead box transcription factors function in human cancers. Oncotarget 2017;8:12433-50. [PMID: 27999212 DOI: 10.18632/oncotarget.14015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
39 Zheng S, Qiao G, Min D, Zhang Z, Lin F, Yang Q, Feng T, Tang L, Sun Y, Zhao H, Li H, Yu W, Yang Y, Shen Z, Yao Y. Heterogeneous expression and biological function of ubiquitin carboxy-terminal hydrolase-L1 in osteosarcoma. Cancer Letters 2015;359:36-46. [DOI: 10.1016/j.canlet.2014.12.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
40 Lin L, He Y, Xi BL, Zheng HC, Chen Q, Li J, Hu Y, Ye MH, Chen P, Qu Y. MiR-135a Suppresses Calcification in Senescent VSMCs by Regulating KLF4/STAT3 Pathway. Curr Vasc Pharmacol 2016;14:211-8. [PMID: 26202084 DOI: 10.2174/1570161113666150722151817] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
41 Moritoki Y, Hayashi Y, Mizuno K, Kamisawa H, Nishio H, Kurokawa S, Ugawa S, Kojima Y, Kohri K. Expression Profiling of microRNA in Cryptorchid Testes: miR-135a Contributes to the Maintenance of Spermatogonial Stem Cells by Regulating FoxO1. Journal of Urology 2014;191:1174-80. [DOI: 10.1016/j.juro.2013.10.137] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
42 Teng L, Wang K, Liu Y, Ma Y, Chen W, Bi L. Based on Integrated Bioinformatics Analysis Identification of Biomarkers in Hepatocellular Carcinoma Patients from Different Regions. Biomed Res Int 2019;2019:1742341. [PMID: 31886176 DOI: 10.1155/2019/1742341] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
43 Pang Y, Mao C, Liu S. Encoding activities of non-coding RNAs. Theranostics 2018;8:2496-507. [PMID: 29721095 DOI: 10.7150/thno.24677] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
44 Turato C, Simonato D, Quarta S, Gatta A, Pontisso P. MicroRNAs and SerpinB3 in hepatocellular carcinoma. Life Sci. 2014;100:9-17. [PMID: 24496037 DOI: 10.1016/j.lfs.2014.01.073] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
45 Morishita A, Masaki T. miRNA in hepatocellular carcinoma. Hepatol Res. 2015;45:128-141. [PMID: 25040738 DOI: 10.1111/hepr.12386] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 8.6] [Reference Citation Analysis]
46 Lankisch TO, Voigtländer T, Manns MP, Holzmann A, Dangwal S, Thum T. MicroRNAs in the bile of patients with biliary strictures after liver transplantation. Liver Transpl 2014;20:673-8. [PMID: 24648209 DOI: 10.1002/lt.23872] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
47 Elemeery MN. Micro-RNA in Hepatocellular Carcinoma - Related Hepatitis C Virus Patients in Correlation to Disease Progression. In: Shahid I, editor. Hepatitis C - From Infection to Cure. InTech; 2018. [DOI: 10.5772/intechopen.76209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
48 Zhao J, Xie Y. Progress in research of hepatocellular carcinoma with tumor thrombus. Shijie Huaren Xiaohua Zazhi 2019; 27(20): 1239-1247 [DOI: 10.11569/wcjd.v27.i20.1239] [Reference Citation Analysis]
49 Si L, Xu L, Yin L, Qi Y, Han X, Xu Y, Zhao Y, Liu K, Peng J. Potent effects of dioscin against pancreatic cancer via miR-149-3P-mediated inhibition of the Akt1 signalling pathway. Br J Pharmacol 2017;174:553-68. [PMID: 28095588 DOI: 10.1111/bph.13718] [Cited by in Crossref: 32] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
50 Fu Y, Wei X, Tang C, Li J, Liu R, Shen A, Wu Z. Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma. Oncol Lett. 2013;6:1811-1815. [PMID: 24260081 DOI: 10.3892/ol.2013.1638] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
51 Yang X, Wu D, Du H, Nie F, Pang X, Xu Y. MicroRNA-135a is involved in podocyte injury in a transient receptor potential channel 1-dependent manner. Int J Mol Med 2017;40:1511-9. [PMID: 28949388 DOI: 10.3892/ijmm.2017.3152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
52 Wijayakumara DD, Mackenzie PI, Mckinnon RA, Hu DG, Meech R. Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells. J Pharmacol Exp Ther 2017;361:386-97. [DOI: 10.1124/jpet.116.239707] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
53 Wang L, Yue Y, Wang X, Jin H. Function and clinical potential of microRNAs in hepatocellular carcinoma. Oncol Lett. 2015;10:3345-3353. [PMID: 26788134 DOI: 10.3892/ol.2015.3759] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
54 Zhang Y, Jiang W, Yang J, Huang J, Kang G, Hu H, Xie S. Downregulation of lysyl oxidase‐like 4 LOXL4 by miR‐135a‐5p promotes lung cancer progression in vitro and in vivo. J Cell Physiol 2019;234:18679-87. [DOI: 10.1002/jcp.28508] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
55 Han J, Liu S, Zhang Y, Xu Y, Jiang Y, Zhang C, Li C, Li X. MiRSEA: Discovering the pathways regulated by dysfunctional MicroRNAs. Oncotarget 2016;7:55012-25. [PMID: 27474169 DOI: 10.18632/oncotarget.10839] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
56 Zhang Y, Wei C, Guo CC, Bi RX, Xie J, Guan DH, Yang CH, Jiang YH. Prognostic value of microRNAs in hepatocellular carcinoma: a meta-analysis. Oncotarget 2017;8:107237-57. [PMID: 29291025 DOI: 10.18632/oncotarget.20883] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
57 Mao XP, Zhang LS, Huang B, Zhou SY, Liao J, Chen LW, Qiu SP, Chen JX. Mir-135a enhances cellular proliferation through post-transcriptionally regulating PHLPP2 and FOXO1 in human bladder cancer. J Transl Med 2015;13:86. [PMID: 25888950 DOI: 10.1186/s12967-015-0438-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
58 Cheng S, Yang J, Shen F, Zhou W, Wang Y, Cong W, Yang GS, Cheng H, Hu H, Gao C, Guo J, Li A, Meng Y, Jiang X, Yang Y, Qian G, Luo M, Hu B, Man X, Zhang B, Su C, Zhou F, Li N, Shi J, Wang M, Zheng Y, Guo W, Sun J, Wang H, Lau WY, Wu MC. Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement. Oncotarget 2016;7:40816-29. [PMID: 27027235 DOI: 10.18632/oncotarget.8386] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
59 Anwar SL, Lehmann U. DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma. World J Gastroenterol 2014; 20(24): 7894-7913 [PMID: 24976726 DOI: 10.3748/wjg.v20.i24.7894] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 50] [Article Influence: 6.5] [Reference Citation Analysis]
60 Liu SY. Abnormal regulation of non-coding RNAs plays a role in development and progression of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2019; 27(18): 1107-1113 [DOI: 10.11569/wcjd.v27.i18.1107] [Reference Citation Analysis]
61 Chen ZH, Ni QZ, Zhang XP, Ma N, Feng JK, Wang K, Li JJ, Xie D, Ma XY, Cheng SQ. NET1 promotes HCC growth and metastasis in vitro and in vivo via activating the Akt signaling pathway. Aging (Albany NY) 2021;13:10672-87. [PMID: 33839702 DOI: 10.18632/aging.202845] [Reference Citation Analysis]
62 Sun J, Lu H, Wang X, Jin H. MicroRNAs in hepatocellular carcinoma: regulation, function, and clinical implications. ScientificWorldJournal 2013;2013:924206. [PMID: 23431261 DOI: 10.1155/2013/924206] [Cited by in Crossref: 37] [Cited by in F6Publishing: 53] [Article Influence: 4.1] [Reference Citation Analysis]
63 Anwar SL, Lehmann U. MicroRNAs: Emerging Novel Clinical Biomarkers for Hepatocellular Carcinomas. J Clin Med. 2015;4:1631-1650. [PMID: 26295264 DOI: 10.3390/jcm4081631] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
64 Morishita A, Oura K, Tadokoro T, Fujita K, Tani J, Masaki T. MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review. Cancers (Basel) 2021;13:514. [PMID: 33572780 DOI: 10.3390/cancers13030514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
65 Zhu P, Liao Y, Fan J, Li X, Su L, Li J, Yuan S, Yu J, Liao W. Preoperative prediction of hepatocellular carcinoma with portal vein tumor thrombus based on conventional data. Oncotarget. 2017;8:104227-104237. [PMID: 29262635 DOI: 10.18632/oncotarget.22198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
66 Zhao X, Wang L, Chen G. Joint Covariate Detection on Expression Profiles for Identifying MicroRNAs Related to Venous Metastasis in Hepatocellular Carcinoma. Sci Rep 2017;7:5349. [PMID: 28706271 DOI: 10.1038/s41598-017-05776-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
67 Erstad DJ, Fuchs BC, Tanabe KK. Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy. Cancer 2018;124:3084-104. [DOI: 10.1002/cncr.31257] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
68 Cheng YQ, Wang K, Zhang XP, Wei XB, Jiang YB, Hu YR, Mao FF, Guo WX, Shi J, Cheng SQ. Thrombocytopenia: A prognostic factor for hepatocellular carcinoma patients with portal vein tumor thrombus after hepatectomy. J Gastroenterol Hepatol 2019;34:1214-21. [PMID: 30402968 DOI: 10.1111/jgh.14537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
69 Chao C, Sang C, Wang M, Wang Z, Li Y, Luo G, Zhang X. Prognostic significance of microRNA-135 in patients with digestive system cancers: a systematic review and meta-analysis. Biosci Rep 2019;39:BSR20190845. [PMID: 31803920 DOI: 10.1042/BSR20190845] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Conti L, Ruiu R, Barutello G, Macagno M, Bandini S, Cavallo F, Lanzardo S. Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice. Biomed Res Int 2014;2014:534969. [PMID: 25136593 DOI: 10.1155/2014/534969] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
71 Grant GD, Brooks L 3rd, Zhang X, Mahoney JM, Martyanov V, Wood TA, Sherlock G, Cheng C, Whitfield ML. Identification of cell cycle-regulated genes periodically expressed in U2OS cells and their regulation by FOXM1 and E2F transcription factors. Mol Biol Cell 2013;24:3634-50. [PMID: 24109597 DOI: 10.1091/mbc.E13-05-0264] [Cited by in Crossref: 118] [Cited by in F6Publishing: 98] [Article Influence: 13.1] [Reference Citation Analysis]
72 Wu H, Huang M, Cao P, Wang T, Shu Y, Liu P. MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation. Cancer Biol Ther 2012;13:281-8. [PMID: 22310976 DOI: 10.4161/cbt.18943] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 5.8] [Reference Citation Analysis]
73 Gupta R, Arkatkar T, Yu JJ, Wali S, Haskins WE, Chambers JP, Murthy AK, Bakar SA, Guentzel MN, Arulanandam BP. Chlamydia muridarum infection associated host MicroRNAs in the murine genital tract and contribution to generation of host immune response. Am J Reprod Immunol 2015;73:126-40. [PMID: 24976530 DOI: 10.1111/aji.12281] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
74 Dang Z, Xu WH, Lu P, Wu N, Liu J, Ruan B, Zhou L, Song WJ, Dou KF. MicroRNA-135a inhibits cell proliferation by targeting Bmi1 in pancreatic ductal adenocarcinoma. Int J Biol Sci 2014;10:733-45. [PMID: 25013381 DOI: 10.7150/ijbs.8097] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
75 Halasi M, Gartel AL. FOX(M1) news--it is cancer. Mol Cancer Ther 2013;12:245-54. [PMID: 23443798 DOI: 10.1158/1535-7163.MCT-12-0712] [Cited by in Crossref: 129] [Cited by in F6Publishing: 94] [Article Influence: 14.3] [Reference Citation Analysis]
76 Voigtländer T, Gupta SK, Thum S, Fendrich J, Manns MP, Lankisch TO, Thum T. MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma. PLoS One 2015;10:e0139305. [PMID: 26431155 DOI: 10.1371/journal.pone.0139305] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
77 Kedmi M, Ben-Chetrit N, Körner C, Mancini M, Ben-Moshe NB, Lauriola M, Lavi S, Biagioni F, Carvalho S, Cohen-Dvashi H, Schmitt F, Wiemann S, Blandino G, Yarden Y. EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer. Sci Signal 2015;8:ra29. [PMID: 25783158 DOI: 10.1126/scisignal.2005866] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
78 He F, Peng F, Xia X, Zhao C, Luo Q, Guan W, Li Z, Yu X, Huang F. MiR-135a promotes renal fibrosis in diabetic nephropathy by regulating TRPC1. Diabetologia 2014;57:1726-36. [DOI: 10.1007/s00125-014-3282-0] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 10.8] [Reference Citation Analysis]
79 Chen P, Duan X, Li X, Li J, Ba Q, Wang H. HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1α. Oncogene 2020;39:2863-76. [PMID: 32034309 DOI: 10.1038/s41388-020-1190-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
80 Lyra-González I, Flores-Fong LE, González-García I, Medina-Preciado D, Armendáriz-Borunda J. MicroRNAs dysregulation in hepatocellular carcinoma: Insights in genomic medicine. World J Hepatol 2015; 7(11): 1530-1540 [PMID: 26085912 DOI: 10.4254/wjh.v7.i11.1530] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
81 Leung CO, Deng W, Ye TM, Ngan HY, Tsao SW, Cheung AN, Pang RT, Yeung WS. miR-135a leads to cervical cancer cell transformation through regulation of β-catenin via a SIAH1-dependent ubiquitin proteosomal pathway. Carcinogenesis 2014;35:1931-40. [PMID: 24503442 DOI: 10.1093/carcin/bgu032] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
82 El Tayebi HM, Hosny KA, Esmat G, Breuhahn K, Abdelaziz AI. miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma. FEBS Lett. 2012;586:3309-3316. [PMID: 22819824 DOI: 10.1016/j.febslet.2012.06.054] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
83 Liu S, Cheng K, Zhang H, Kong R, Wang S, Mao C, Liu S. Methylation Status of the Nanog Promoter Determines the Switch between Cancer Cells and Cancer Stem Cells. Adv Sci (Weinh) 2020;7:1903035. [PMID: 32154082 DOI: 10.1002/advs.201903035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
84 Arigoni M, Barutello G, Riccardo F, Ercole E, Cantarella D, Orso F, Conti L, Lanzardo S, Taverna D, Merighi I. miR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2. Am J Pathol. 2013;182:2058-2070. [PMID: 23623609 DOI: 10.1016/j.ajpath.2013.02.046] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
85 Takahashi K, Yan I, Wen HJ, Patel T. microRNAs in liver disease: from diagnostics to therapeutics. Clin Biochem. 2013;46:946-952. [PMID: 23396165 DOI: 10.1016/j.clinbiochem] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
86 Zhang H, Ye J, Weng X, Liu F, He L, Zhou D, Liu Y. Comparative transcriptome analysis reveals that the extracellular matrix receptor interaction contributes to the venous metastases of hepatocellular carcinoma. Cancer Genet 2015;208:482-91. [PMID: 26271415 DOI: 10.1016/j.cancergen.2015.06.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
87 Weidle UH, Schmid D, Birzele F, Brinkmann U. MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance. Cancer Genomics Proteomics 2020;17:1-21. [PMID: 31882547 DOI: 10.21873/cgp.20163] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
88 Sun JX, Shi J, Li N, Guo WX, Wu MC, Lau WY, Cheng SQ. Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma. Cancer Biol Med 2016;13:452-8. [PMID: 28154776 DOI: 10.20892/j.issn.2095-3941.2016.0059] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
89 Zhou W, Fang DL, He Y. Screening potential prognostic biomarkers for portal vein emboli in patients with hepatocellular carcinoma. J Gastrointest Oncol 2021;12:1927-38. [PMID: 34532139 DOI: 10.21037/jgo-21-433] [Reference Citation Analysis]
90 von Felden J, Heim D, Schulze K, Krech T, Ewald F, Nashan B, Lohse AW, Wege H. High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection. BMC Cancer 2017;17:60. [PMID: 28100188 DOI: 10.1186/s12885-017-3053-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
91 Xu Z, Han Y, Liu J, Jiang F, Hu H, Wang Y, Liu Q, Gong Y, Li X. MiR-135b-5p and MiR-499a-3p Promote Cell Proliferation and Migration in Atherosclerosis by Directly Targeting MEF2C. Sci Rep 2015;5:12276. [PMID: 26184978 DOI: 10.1038/srep12276] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 6.7] [Reference Citation Analysis]
92 Zhou L, Li J, Shao QQ, Guo JC, Liang ZY, Zhou WX, Zhang TP, You L, Zhao YP. Expression and Significances of MTSS1 in Pancreatic Cancer. Pathol Oncol Res 2016;22:7-14. [PMID: 26198729 DOI: 10.1007/s12253-015-9963-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
93 Tang Y, Yu H, Zhang L, Wang K, Guo W, Shi J, Liu S, Wu M, Wang H, Cheng S. Experimental study on enhancement of the metastatic potential of portal vein tumor thrombus-originated hepatocellular carcinoma cells using portal vein serum. Chin J Cancer Res 2014;26:588-95. [PMID: 25400425 DOI: 10.3978/j.issn.1000-9604.2014.10.07] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
94 Liao W, Wang Y, Liao Y, He S, Jin J. Preoperative Aspartate Aminotransferase to White Blood Cell Count Ratio Predicting Postoperative Outcomes of Hepatocellular Carcinoma. Medicine (Baltimore) 2016;95:e3345. [PMID: 27057915 DOI: 10.1097/MD.0000000000003345] [Reference Citation Analysis]
95 Zeleniak AE, Huang W, Fishel ML, Hill R. PTEN-Dependent Stabilization of MTSS1 Inhibits Metastatic Phenotype in Pancreatic Ductal Adenocarcinoma. Neoplasia 2018;20:12-24. [PMID: 29175021 DOI: 10.1016/j.neo.2017.10.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
96 Deng X, Cheng J, Zhan N, Chen J, Zhan Y, Ni Y, Liao C. MicroRNA-135a expression is upregulated in hepatocellular carcinoma and targets long non-coding RNA TONSL-AS1 to suppress cell proliferation. Oncol Lett 2021;22:808. [PMID: 34630715 DOI: 10.3892/ol.2021.13069] [Reference Citation Analysis]
97 Branco-Price C, Evans CE, Johnson RS. Endothelial hypoxic metabolism in carcinogenesis and dissemination: HIF-A isoforms are a NO metastatic phenomenon. Oncotarget 2013;4:2567-76. [PMID: 24318195 DOI: 10.18632/oncotarget.1461] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
98 Yang Y, Chen L, Gu J, Zhang H, Yuan J, Lian Q, Lv G, Wang S, Wu Y, Yang YT, Wang D, Liu Y, Tang J, Luo G, Li Y, Hu L, Sun X, Wang D, Guo M, Xi Q, Xi J, Wang H, Zhang MQ, Lu ZJ. Recurrently deregulated lncRNAs in hepatocellular carcinoma. Nat Commun 2017;8:14421. [PMID: 28194035 DOI: 10.1038/ncomms14421] [Cited by in Crossref: 150] [Cited by in F6Publishing: 164] [Article Influence: 30.0] [Reference Citation Analysis]
99 Yamazaki S, Takayama T, Kurokawa T, Shimamoto N, Mitsuka Y, Yoshida N, Higaki T, Sugitani M. Next-generation des-r-carboxy prothrombin for immunohistochemical assessment of vascular invasion by hepatocellular carcinoma. BMC Surg 2020;20:201. [PMID: 32928172 DOI: 10.1186/s12893-020-00862-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
100 Khan AR, Wei X, Xu X. Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. J Hepatocell Carcinoma 2021;8:1089-115. [PMID: 34522691 DOI: 10.2147/JHC.S318070] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
101 Chen Y, Zhang J, Wang H, Zhao J, Xu C, Du Y, Luo X, Zheng F, Liu R, Zhang H, Ma D. miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10. BMC Cancer 2012;12:111. [PMID: 22439757 DOI: 10.1186/1471-2407-12-111] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 6.4] [Reference Citation Analysis]
102 Takahashi K, Yan I, Wen HJ, Patel T. microRNAs in liver disease: from diagnostics to therapeutics. Clin Biochem 2013;46:946-52. [PMID: 23396165 DOI: 10.1016/j.clinbiochem.2013.01.025] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
103 Witwer KW. Data submission and quality in microarray-based microRNA profiling. Clin Chem 2013;59:392-400. [PMID: 23358751 DOI: 10.1373/clinchem.2012.193813] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
104 Huang KT, Kuo IY, Tsai MC, Wu CH, Hsu LW, Chen LY, Kung CP, Cheng YF, Goto S, Chou YW, Chen CL, Lin CC, Chen KD. Factor VII-Induced MicroRNA-135a Inhibits Autophagy and Is Associated with Poor Prognosis in Hepatocellular Carcinoma. Mol Ther Nucleic Acids 2017;9:274-83. [PMID: 29246306 DOI: 10.1016/j.omtn.2017.10.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
105 Otsuka M, Kishikawa T, Yoshikawa T, Ohno M, Takata A, Shibata C, Koike K. The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects. J Gastroenterol. 2014;49:173-184. [PMID: 24258409 DOI: 10.1007/s00535-013-0909-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
106 Vajtai Z, Korngold E, Hooper JE, Sheppard BC, Foster BR, Coakley FV. Suprarenal retroperitoneal liposarcoma with intracaval tumor thrombus: an imaging mimic of adrenocortical carcinoma. Clin Imaging 2014;38:75-7. [PMID: 24075490 DOI: 10.1016/j.clinimag.2013.08.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
107 Meng X, Thiel KW, Leslie KK. Drug resistance mediated by AEG-1/MTDH/LYRIC. Adv Cancer Res. 2013;120:135-157. [PMID: 23889990 DOI: 10.1016/B978-0-12-401676-7.00005-X] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
108 Ziogas IA, Sioutas G, Mylonas KS, Tsoulfas G. Role of MicroRNA in the Diagnosis and Management of Hepatocellular Carcinoma. Microrna 2020;9:25-40. [PMID: 31218966 DOI: 10.2174/2211536608666190619155406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
109 Zhang C, Chen X, Chen X, Wang X, Ji A, Jiang L, Sang F, Li F. miR-135a acts as a tumor suppressor in gastric cancer in part by targeting KIFC1. Onco Targets Ther 2016;9:3555-63. [PMID: 27366092 DOI: 10.2147/OTT.S105736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
110 Van Renne N, Roca Suarez AA, Duong FHT, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF, Lupberger J. miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut. 2018;67:953-962. [PMID: 28159835 DOI: 10.1136/gutjnl-2016-312270] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
111 Ahmad A, Zhang W, Wu M, Tan S, Zhu T. Tumor-suppressive miRNA-135a inhibits breast cancer cell proliferation by targeting ELK1 and ELK3 oncogenes. Genes Genomics 2018;40:243-51. [PMID: 29892795 DOI: 10.1007/s13258-017-0624-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
112 Ghidini M, Braconi C. Non-Coding RNAs in Primary Liver Cancer. Front Med (Lausanne). 2015;2:36. [PMID: 26131450 DOI: 10.3389/fmed.2015.00036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
113 Yang N, Ekanem NR, Sakyi CA, Ray SD. Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics. Adv Drug Deliv Rev. 2015;81:62-74. [PMID: 25450260 DOI: 10.1016/j.addr.2014.10.029] [Cited by in Crossref: 108] [Cited by in F6Publishing: 115] [Article Influence: 13.5] [Reference Citation Analysis]
114 Ming Z, Ding W, Yuan R, Jin J, Li X. Differential co-expression analysis of venous thromboembolism based on gene expression profile data. Exp Ther Med 2016;11:2193-200. [PMID: 27284300 DOI: 10.3892/etm.2016.3208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]